Jeannette Lee
Concepts (463)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 20 | 2023 | 357 | 3.080 |
Why?
| Anus Neoplasms | 10 | 2023 | 24 | 2.240 |
Why?
| Stroke | 6 | 2024 | 492 | 1.720 |
Why?
| Acquired Immunodeficiency Syndrome | 11 | 2022 | 54 | 1.680 |
Why?
| Prostatic Hyperplasia | 10 | 2015 | 39 | 1.520 |
Why?
| Brain | 8 | 2024 | 1328 | 1.420 |
Why?
| Parkinson Disease | 2 | 2023 | 154 | 1.330 |
Why?
| Randomized Controlled Trials as Topic | 8 | 2024 | 549 | 1.300 |
Why?
| Chlamydia Infections | 8 | 2017 | 77 | 1.270 |
Why?
| Sarcoma, Kaposi | 12 | 2022 | 72 | 1.100 |
Why?
| Papillomavirus Infections | 5 | 2022 | 155 | 1.070 |
Why?
| Chlamydia trachomatis | 6 | 2017 | 30 | 1.070 |
Why?
| Lymphoma, AIDS-Related | 10 | 2020 | 16 | 1.040 |
Why?
| Brain Ischemia | 2 | 2023 | 161 | 0.950 |
Why?
| Mesenchymal Stem Cell Transplantation | 1 | 2024 | 18 | 0.940 |
Why?
| Plant Extracts | 5 | 2013 | 190 | 0.940 |
Why?
| Serenoa | 5 | 2013 | 7 | 0.910 |
Why?
| Humans | 100 | 2024 | 49974 | 0.880 |
Why?
| Rural Population | 4 | 2023 | 540 | 0.830 |
Why?
| Phytotherapy | 3 | 2012 | 44 | 0.830 |
Why?
| Umbilical Cord | 2 | 2020 | 35 | 0.820 |
Why?
| Lymphoma, Non-Hodgkin | 6 | 2021 | 60 | 0.750 |
Why?
| Middle Aged | 50 | 2021 | 12069 | 0.750 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2021 | 989 | 0.750 |
Why?
| Research Design | 5 | 2022 | 344 | 0.720 |
Why?
| Male | 61 | 2024 | 25241 | 0.700 |
Why?
| Neonatal Abstinence Syndrome | 3 | 2024 | 25 | 0.690 |
Why?
| Fetal Blood | 2 | 2019 | 68 | 0.690 |
Why?
| Adult | 48 | 2022 | 13236 | 0.660 |
Why?
| Infarction, Middle Cerebral Artery | 4 | 2024 | 40 | 0.660 |
Why?
| Inflammation | 3 | 2021 | 604 | 0.650 |
Why?
| Rats | 8 | 2024 | 3305 | 0.650 |
Why?
| Patient Participation | 1 | 2018 | 66 | 0.610 |
Why?
| Vaginosis, Bacterial | 2 | 2015 | 8 | 0.580 |
Why?
| Decision Making | 1 | 2018 | 265 | 0.550 |
Why?
| Neoplasms | 3 | 2023 | 1235 | 0.540 |
Why?
| Mammography | 1 | 2016 | 96 | 0.540 |
Why?
| Female | 48 | 2024 | 26472 | 0.520 |
Why?
| Antineoplastic Agents | 9 | 2023 | 1171 | 0.510 |
Why?
| Aged | 28 | 2020 | 9310 | 0.510 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 6 | 2015 | 47 | 0.500 |
Why?
| Population Density | 1 | 2014 | 15 | 0.490 |
Why?
| Pelvic Inflammatory Disease | 2 | 2018 | 8 | 0.490 |
Why?
| AIDS-Related Opportunistic Infections | 5 | 2016 | 40 | 0.480 |
Why?
| Carcinoma in Situ | 3 | 2013 | 73 | 0.470 |
Why?
| Rats, Sprague-Dawley | 7 | 2024 | 1597 | 0.460 |
Why?
| Cytokines | 5 | 2023 | 612 | 0.460 |
Why?
| Anti-Bacterial Agents | 5 | 2020 | 744 | 0.450 |
Why?
| Uterine Cervicitis | 1 | 2013 | 3 | 0.450 |
Why?
| Animals | 14 | 2024 | 13187 | 0.440 |
Why?
| Hydrocephalus, Normal Pressure | 1 | 2012 | 1 | 0.440 |
Why?
| Urethritis | 2 | 2012 | 5 | 0.440 |
Why?
| Finasteride | 4 | 2015 | 4 | 0.420 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 105 | 0.420 |
Why?
| Research Subjects | 1 | 2013 | 50 | 0.420 |
Why?
| Guideline Adherence | 1 | 2013 | 133 | 0.410 |
Why?
| Subarachnoid Hemorrhage | 1 | 2012 | 65 | 0.400 |
Why?
| Breast Neoplasms | 3 | 2017 | 1174 | 0.400 |
Why?
| Patient Dropouts | 1 | 2012 | 53 | 0.400 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 154 | 0.400 |
Why?
| Urologic Diseases | 1 | 2011 | 10 | 0.390 |
Why?
| Analgesics, Opioid | 4 | 2024 | 552 | 0.380 |
Why?
| HIV-1 | 6 | 2020 | 55 | 0.380 |
Why?
| Lung Neoplasms | 2 | 2013 | 606 | 0.370 |
Why?
| Stem Cell Transplantation | 2 | 2023 | 181 | 0.360 |
Why?
| Disease Models, Animal | 5 | 2024 | 1455 | 0.360 |
Why?
| United States | 10 | 2023 | 4860 | 0.350 |
Why?
| Young Adult | 16 | 2018 | 3958 | 0.340 |
Why?
| Patient Selection | 1 | 2011 | 253 | 0.340 |
Why?
| Quality of Life | 6 | 2024 | 836 | 0.340 |
Why?
| Asthma | 2 | 2024 | 281 | 0.340 |
Why?
| Lymphedema | 2 | 2022 | 43 | 0.340 |
Why?
| HIV Seropositivity | 3 | 2021 | 27 | 0.340 |
Why?
| Lower Urinary Tract Symptoms | 3 | 2013 | 6 | 0.330 |
Why?
| Intestinal Mucosa | 2 | 2021 | 225 | 0.330 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2017 | 485 | 0.320 |
Why?
| Gonorrhea | 2 | 2020 | 9 | 0.310 |
Why?
| Azithromycin | 4 | 2020 | 25 | 0.310 |
Why?
| Stem Cells | 2 | 2019 | 171 | 0.300 |
Why?
| Risk Factors | 8 | 2022 | 3613 | 0.290 |
Why?
| Th1 Cells | 2 | 2017 | 52 | 0.290 |
Why?
| Vascular Endothelial Growth Factor A | 4 | 2017 | 201 | 0.270 |
Why?
| Treatment Outcome | 17 | 2020 | 5141 | 0.270 |
Why?
| Mycoplasma genitalium | 2 | 2018 | 2 | 0.270 |
Why?
| Doxazosin | 3 | 2015 | 3 | 0.260 |
Why?
| Mycoplasma Infections | 2 | 2018 | 7 | 0.260 |
Why?
| Anti-Infective Agents | 2 | 2020 | 95 | 0.260 |
Why?
| Prospective Studies | 11 | 2022 | 2364 | 0.260 |
Why?
| Doxycycline | 3 | 2015 | 32 | 0.260 |
Why?
| Cyclophosphamide | 9 | 2021 | 165 | 0.260 |
Why?
| Cancer Vaccines | 1 | 2006 | 78 | 0.260 |
Why?
| Vincristine | 8 | 2021 | 89 | 0.250 |
Why?
| Multicenter Studies as Topic | 4 | 2024 | 84 | 0.250 |
Why?
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 565 | 0.240 |
Why?
| Adolescent | 13 | 2022 | 6356 | 0.240 |
Why?
| Air Filters | 1 | 2024 | 1 | 0.240 |
Why?
| Double-Blind Method | 4 | 2013 | 681 | 0.240 |
Why?
| Thymus Gland | 2 | 2021 | 42 | 0.240 |
Why?
| Air Pollution, Indoor | 1 | 2024 | 25 | 0.230 |
Why?
| CD4 Lymphocyte Count | 7 | 2020 | 32 | 0.230 |
Why?
| Prevalence | 6 | 2021 | 944 | 0.230 |
Why?
| Bronchiolitis | 1 | 2024 | 27 | 0.230 |
Why?
| 5-alpha Reductase Inhibitors | 2 | 2015 | 3 | 0.230 |
Why?
| Homosexuality, Male | 3 | 2022 | 51 | 0.230 |
Why?
| Hyperbaric Oxygenation | 1 | 2023 | 14 | 0.230 |
Why?
| Substantia Nigra | 1 | 2023 | 14 | 0.230 |
Why?
| alpha-Synuclein | 1 | 2023 | 10 | 0.230 |
Why?
| Doxorubicin | 8 | 2021 | 233 | 0.220 |
Why?
| Transplantation Conditioning | 2 | 2018 | 83 | 0.220 |
Why?
| Nervous System Diseases | 1 | 2024 | 88 | 0.220 |
Why?
| Informatics | 1 | 2023 | 8 | 0.220 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2017 | 388 | 0.220 |
Why?
| Herpesvirus 8, Human | 5 | 2020 | 91 | 0.220 |
Why?
| Prednisone | 7 | 2021 | 99 | 0.220 |
Why?
| Cross-Sectional Studies | 3 | 2021 | 1557 | 0.210 |
Why?
| Follow-Up Studies | 8 | 2019 | 2182 | 0.210 |
Why?
| Brachytherapy | 1 | 2022 | 48 | 0.210 |
Why?
| Astrocytes | 1 | 2024 | 145 | 0.210 |
Why?
| Child | 8 | 2024 | 6847 | 0.210 |
Why?
| Watchful Waiting | 1 | 2022 | 27 | 0.210 |
Why?
| Feasibility Studies | 2 | 2021 | 375 | 0.210 |
Why?
| Medical Records | 1 | 2022 | 83 | 0.210 |
Why?
| Absorptiometry, Photon | 1 | 2003 | 154 | 0.210 |
Why?
| Substance Withdrawal Syndrome | 1 | 2023 | 169 | 0.200 |
Why?
| Vitamin D Deficiency | 1 | 2022 | 44 | 0.200 |
Why?
| Genome-Wide Association Study | 3 | 2018 | 166 | 0.200 |
Why?
| Viral Load | 6 | 2020 | 76 | 0.200 |
Why?
| Brain Injuries | 1 | 2023 | 160 | 0.200 |
Why?
| Vaccines | 1 | 2022 | 50 | 0.200 |
Why?
| Case-Control Studies | 3 | 2014 | 1131 | 0.200 |
Why?
| Vaccination | 3 | 2022 | 266 | 0.200 |
Why?
| Precancerous Conditions | 1 | 2022 | 83 | 0.200 |
Why?
| Mouth Diseases | 1 | 2021 | 5 | 0.200 |
Why?
| Clinical Trials as Topic | 5 | 2020 | 461 | 0.200 |
Why?
| Lymphocyte Activation | 3 | 2017 | 172 | 0.200 |
Why?
| Papillomaviridae | 2 | 2016 | 102 | 0.190 |
Why?
| Mass Screening | 2 | 2015 | 353 | 0.190 |
Why?
| Pluripotent Stem Cells | 1 | 2021 | 6 | 0.190 |
Why?
| Neoplasm Staging | 4 | 2022 | 740 | 0.190 |
Why?
| Physical Conditioning, Animal | 1 | 2021 | 52 | 0.190 |
Why?
| Primary Health Care | 2 | 2022 | 358 | 0.190 |
Why?
| Drug Therapy, Combination | 5 | 2015 | 377 | 0.190 |
Why?
| T-Lymphocyte Subsets | 2 | 2017 | 39 | 0.190 |
Why?
| Papillomavirus Vaccines | 2 | 2013 | 61 | 0.190 |
Why?
| Cross-Over Studies | 1 | 2021 | 224 | 0.190 |
Why?
| Vagina | 2 | 2018 | 45 | 0.190 |
Why?
| Etoposide | 5 | 2021 | 72 | 0.180 |
Why?
| Anti-HIV Agents | 3 | 2020 | 42 | 0.180 |
Why?
| Spleen | 1 | 2021 | 172 | 0.180 |
Why?
| Enzyme Inhibitors | 2 | 2016 | 391 | 0.180 |
Why?
| Genes, myc | 1 | 2020 | 40 | 0.180 |
Why?
| Gene Frequency | 2 | 2017 | 94 | 0.180 |
Why?
| Overweight | 1 | 2022 | 219 | 0.180 |
Why?
| Transplantation, Autologous | 3 | 2018 | 466 | 0.180 |
Why?
| Aged, 80 and over | 5 | 2013 | 3129 | 0.180 |
Why?
| Cell Differentiation | 2 | 2021 | 651 | 0.170 |
Why?
| Uterine Cervical Neoplasms | 1 | 2022 | 277 | 0.170 |
Why?
| Dihydroxyphenylalanine | 1 | 2019 | 5 | 0.170 |
Why?
| Dopaminergic Neurons | 1 | 2019 | 18 | 0.170 |
Why?
| Empathy | 1 | 2019 | 46 | 0.170 |
Why?
| Ablation Techniques | 1 | 2019 | 20 | 0.170 |
Why?
| Infant, Newborn | 5 | 2024 | 2772 | 0.160 |
Why?
| Social Environment | 1 | 2019 | 80 | 0.160 |
Why?
| Altruism | 1 | 2018 | 13 | 0.160 |
Why?
| Central Nervous System Diseases | 1 | 2019 | 27 | 0.160 |
Why?
| Sodium, Dietary | 1 | 2019 | 26 | 0.160 |
Why?
| Mitochondria | 2 | 2020 | 402 | 0.160 |
Why?
| Asymptomatic Infections | 1 | 2018 | 6 | 0.160 |
Why?
| Dopamine | 1 | 2019 | 171 | 0.160 |
Why?
| Antiviral Agents | 2 | 2013 | 173 | 0.160 |
Why?
| Acoustic Stimulation | 1 | 2018 | 97 | 0.160 |
Why?
| Sexually Transmitted Diseases | 1 | 2018 | 36 | 0.160 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 244 | 0.160 |
Why?
| Energy Metabolism | 1 | 2020 | 282 | 0.150 |
Why?
| Hyperthermia, Induced | 1 | 2019 | 117 | 0.150 |
Why?
| Chlamydia | 1 | 2017 | 8 | 0.150 |
Why?
| Protein Kinase Inhibitors | 2 | 2023 | 204 | 0.150 |
Why?
| Mucous Membrane | 1 | 2017 | 28 | 0.150 |
Why?
| Blood Cells | 1 | 2017 | 43 | 0.150 |
Why?
| Pilot Projects | 3 | 2019 | 699 | 0.150 |
Why?
| Biopsy | 2 | 2022 | 584 | 0.150 |
Why?
| Genetic Predisposition to Disease | 2 | 2018 | 510 | 0.150 |
Why?
| Clostridium Infections | 1 | 2018 | 54 | 0.150 |
Why?
| DNA, Circular | 1 | 2017 | 18 | 0.150 |
Why?
| Antibodies, Bacterial | 1 | 2017 | 28 | 0.150 |
Why?
| Clonal Evolution | 1 | 2017 | 56 | 0.140 |
Why?
| Immunoglobulins | 1 | 2017 | 79 | 0.140 |
Why?
| Immunoglobulin G | 1 | 2017 | 186 | 0.140 |
Why?
| Anus Diseases | 1 | 2016 | 2 | 0.140 |
Why?
| Telemedicine | 1 | 2022 | 448 | 0.140 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2017 | 116 | 0.140 |
Why?
| Mannitol | 1 | 2016 | 14 | 0.140 |
Why?
| Lymph Node Excision | 1 | 2017 | 134 | 0.140 |
Why?
| Thiazoles | 1 | 2016 | 52 | 0.130 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2015 | 8 | 0.130 |
Why?
| Guidelines as Topic | 1 | 2016 | 111 | 0.130 |
Why?
| Diagnostic Self Evaluation | 1 | 2015 | 14 | 0.130 |
Why?
| Comorbidity | 2 | 2018 | 615 | 0.130 |
Why?
| Blood-Brain Barrier | 1 | 2016 | 48 | 0.130 |
Why?
| Anal Canal | 3 | 2023 | 21 | 0.130 |
Why?
| Educational Status | 1 | 2016 | 222 | 0.130 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2017 | 164 | 0.130 |
Why?
| Tinidazole | 2 | 2012 | 2 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 4 | 2013 | 1376 | 0.130 |
Why?
| T-Lymphocytes | 1 | 2017 | 338 | 0.130 |
Why?
| Imidazoles | 1 | 2016 | 119 | 0.130 |
Why?
| Burkitt Lymphoma | 1 | 2015 | 28 | 0.130 |
Why?
| Drug Administration Schedule | 5 | 2020 | 376 | 0.130 |
Why?
| Lymph Nodes | 1 | 2017 | 260 | 0.120 |
Why?
| Menarche | 1 | 2014 | 7 | 0.120 |
Why?
| Stomatitis | 1 | 2014 | 16 | 0.120 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 2014 | 25 | 0.120 |
Why?
| Data Collection | 3 | 2023 | 279 | 0.120 |
Why?
| Immunophenotyping | 2 | 2017 | 109 | 0.120 |
Why?
| Obesity | 3 | 2022 | 1113 | 0.120 |
Why?
| Disease-Free Survival | 5 | 2016 | 454 | 0.120 |
Why?
| Hypogonadism | 1 | 2013 | 10 | 0.120 |
Why?
| Benzamides | 1 | 2013 | 51 | 0.110 |
Why?
| Carcinoma, Squamous Cell | 1 | 2016 | 318 | 0.110 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2018 | 360 | 0.110 |
Why?
| Incidence | 4 | 2018 | 1003 | 0.110 |
Why?
| Urban Population | 1 | 2014 | 151 | 0.110 |
Why?
| SEER Program | 1 | 2013 | 94 | 0.110 |
Why?
| Heart Failure | 1 | 2019 | 458 | 0.110 |
Why?
| Health Surveys | 1 | 2014 | 232 | 0.110 |
Why?
| Organophosphonates | 1 | 2013 | 7 | 0.110 |
Why?
| Testosterone | 1 | 2013 | 139 | 0.110 |
Why?
| Perineum | 1 | 2013 | 24 | 0.110 |
Why?
| Stress, Psychological | 2 | 2019 | 260 | 0.110 |
Why?
| DNA, Viral | 3 | 2020 | 133 | 0.110 |
Why?
| Placebos | 1 | 2013 | 85 | 0.110 |
Why?
| Cytosine | 1 | 2013 | 30 | 0.110 |
Why?
| Adrenergic alpha-Antagonists | 2 | 2009 | 27 | 0.110 |
Why?
| tau Proteins | 1 | 2012 | 26 | 0.110 |
Why?
| Piperazines | 1 | 2013 | 117 | 0.110 |
Why?
| Prostate | 2 | 2015 | 117 | 0.110 |
Why?
| HIV | 3 | 2023 | 24 | 0.110 |
Why?
| Trichomonas Infections | 1 | 2012 | 2 | 0.110 |
Why?
| Trichomonas vaginalis | 1 | 2012 | 3 | 0.110 |
Why?
| Transforming Growth Factor beta1 | 1 | 2012 | 60 | 0.100 |
Why?
| Sleep | 2 | 2024 | 184 | 0.100 |
Why?
| Pyrimidines | 1 | 2013 | 192 | 0.100 |
Why?
| Vulvar Neoplasms | 1 | 2013 | 52 | 0.100 |
Why?
| Time Factors | 5 | 2023 | 2903 | 0.100 |
Why?
| Medicare | 1 | 2013 | 246 | 0.100 |
Why?
| Androgen Antagonists | 1 | 2011 | 11 | 0.100 |
Why?
| Urination Disorders | 1 | 2011 | 23 | 0.100 |
Why?
| Sirolimus | 1 | 2012 | 62 | 0.100 |
Why?
| Antibiotics, Antineoplastic | 1 | 2012 | 78 | 0.100 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2017 | 116 | 0.100 |
Why?
| Kenya | 2 | 2022 | 11 | 0.100 |
Why?
| Quinazolinones | 1 | 2011 | 6 | 0.090 |
Why?
| Human papillomavirus 16 | 2 | 2013 | 44 | 0.090 |
Why?
| Practice Guidelines as Topic | 1 | 2013 | 449 | 0.090 |
Why?
| Arkansas | 1 | 2016 | 1977 | 0.090 |
Why?
| Social Class | 1 | 2011 | 94 | 0.090 |
Why?
| Prognosis | 5 | 2017 | 1942 | 0.090 |
Why?
| Multivariate Analysis | 1 | 2012 | 577 | 0.090 |
Why?
| Methotrexate | 2 | 2015 | 69 | 0.090 |
Why?
| Chronic Disease | 1 | 2012 | 567 | 0.090 |
Why?
| Piperidines | 1 | 2011 | 98 | 0.090 |
Why?
| Plant Bark | 1 | 2009 | 6 | 0.090 |
Why?
| Colorectal Neoplasms | 1 | 2013 | 236 | 0.090 |
Why?
| Valproic Acid | 1 | 2009 | 32 | 0.090 |
Why?
| Multiple Myeloma | 2 | 2014 | 2929 | 0.090 |
Why?
| Ki-67 Antigen | 1 | 2009 | 57 | 0.080 |
Why?
| Socioeconomic Factors | 1 | 2012 | 581 | 0.080 |
Why?
| India | 2 | 2021 | 51 | 0.080 |
Why?
| Logistic Models | 1 | 2012 | 888 | 0.080 |
Why?
| Tetracyclines | 2 | 2006 | 7 | 0.080 |
Why?
| Fruit | 1 | 2009 | 136 | 0.080 |
Why?
| Neoplasm Recurrence, Local | 1 | 2012 | 614 | 0.080 |
Why?
| Cisplatin | 2 | 2022 | 278 | 0.080 |
Why?
| Antiretroviral Therapy, Highly Active | 3 | 2015 | 34 | 0.080 |
Why?
| Glomerulonephritis, IGA | 1 | 2007 | 5 | 0.080 |
Why?
| Survival Analysis | 3 | 2017 | 653 | 0.080 |
Why?
| Galactose | 1 | 2007 | 28 | 0.080 |
Why?
| Immunoglobulin A | 1 | 2007 | 45 | 0.080 |
Why?
| Adaptive Immunity | 2 | 2017 | 32 | 0.080 |
Why?
| Glioblastoma | 1 | 2009 | 92 | 0.070 |
Why?
| Sexual Partners | 2 | 2018 | 29 | 0.070 |
Why?
| Disease Progression | 4 | 2013 | 825 | 0.070 |
Why?
| Regression Analysis | 2 | 2018 | 395 | 0.070 |
Why?
| Chaperonins | 1 | 2006 | 3 | 0.070 |
Why?
| Chaperonin 60 | 1 | 2006 | 5 | 0.070 |
Why?
| Lymphocyte Count | 1 | 2006 | 21 | 0.070 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2006 | 13 | 0.070 |
Why?
| Papillomavirus E7 Proteins | 1 | 2006 | 31 | 0.070 |
Why?
| Viral Vaccines | 1 | 2006 | 12 | 0.070 |
Why?
| Sexual Behavior | 2 | 2018 | 117 | 0.070 |
Why?
| HIV Protease Inhibitors | 1 | 2006 | 2 | 0.070 |
Why?
| Immunohistochemistry | 3 | 2017 | 973 | 0.070 |
Why?
| Interferon-alpha | 1 | 2006 | 47 | 0.070 |
Why?
| Infant | 2 | 2024 | 3567 | 0.070 |
Why?
| Nephrosis, Lipoid | 1 | 2005 | 5 | 0.070 |
Why?
| Arterioles | 1 | 2005 | 33 | 0.070 |
Why?
| Body Mass Index | 2 | 2022 | 652 | 0.070 |
Why?
| Severity of Illness Index | 2 | 2023 | 945 | 0.070 |
Why?
| Brain Neoplasms | 1 | 2009 | 287 | 0.060 |
Why?
| Recombinant Fusion Proteins | 1 | 2006 | 181 | 0.060 |
Why?
| Matrix Metalloproteinase 9 | 3 | 2017 | 88 | 0.060 |
Why?
| Administration, Oral | 4 | 2013 | 426 | 0.060 |
Why?
| Aminoimidazole Carboxamide | 1 | 2004 | 3 | 0.060 |
Why?
| Phenotype | 2 | 2017 | 729 | 0.060 |
Why?
| Leucovorin | 1 | 2004 | 20 | 0.060 |
Why?
| Purines | 1 | 2004 | 38 | 0.060 |
Why?
| Genotype | 2 | 2017 | 537 | 0.060 |
Why?
| Neutropenia | 2 | 2020 | 116 | 0.060 |
Why?
| Confidence Intervals | 2 | 2015 | 156 | 0.060 |
Why?
| Dust | 1 | 2024 | 22 | 0.060 |
Why?
| Particulate Matter | 1 | 2024 | 52 | 0.060 |
Why?
| Arthritis, Rheumatoid | 1 | 2004 | 105 | 0.060 |
Why?
| Carbon | 1 | 2024 | 54 | 0.060 |
Why?
| Folic Acid | 1 | 2004 | 135 | 0.060 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2023 | 78 | 0.060 |
Why?
| Femur Neck | 1 | 2003 | 6 | 0.050 |
Why?
| Africa South of the Sahara | 1 | 2022 | 5 | 0.050 |
Why?
| Hip | 1 | 2003 | 25 | 0.050 |
Why?
| Drug Delivery Systems | 1 | 2024 | 138 | 0.050 |
Why?
| Quality Control | 1 | 2003 | 94 | 0.050 |
Why?
| Bacterial Proteins | 1 | 2006 | 376 | 0.050 |
Why?
| Narcotics | 1 | 2023 | 111 | 0.050 |
Why?
| Sample Size | 1 | 2022 | 37 | 0.050 |
Why?
| Eating | 1 | 2023 | 162 | 0.050 |
Why?
| Breast Feeding | 1 | 2024 | 187 | 0.050 |
Why?
| Femur | 1 | 2003 | 133 | 0.050 |
Why?
| Vitamins | 1 | 2022 | 64 | 0.050 |
Why?
| Spine | 1 | 2003 | 94 | 0.050 |
Why?
| Matrix Metalloproteinase Inhibitors | 1 | 2002 | 10 | 0.050 |
Why?
| Tetracycline | 1 | 2002 | 20 | 0.050 |
Why?
| Radiotherapy Dosage | 1 | 2022 | 244 | 0.050 |
Why?
| Vitamin D | 1 | 2022 | 88 | 0.050 |
Why?
| Tretinoin | 1 | 2002 | 53 | 0.050 |
Why?
| Leg | 1 | 2022 | 122 | 0.050 |
Why?
| Fibroblast Growth Factor 2 | 2 | 2017 | 34 | 0.050 |
Why?
| Museums | 1 | 2021 | 2 | 0.050 |
Why?
| Antibodies, Monoclonal | 1 | 2005 | 459 | 0.050 |
Why?
| Regenerative Medicine | 1 | 2021 | 9 | 0.050 |
Why?
| Alprostadil | 1 | 2021 | 9 | 0.050 |
Why?
| Kidney | 1 | 2005 | 665 | 0.050 |
Why?
| Length of Stay | 1 | 2024 | 619 | 0.050 |
Why?
| Oxygen | 1 | 2023 | 326 | 0.050 |
Why?
| Zimbabwe | 1 | 2020 | 2 | 0.050 |
Why?
| Malawi | 1 | 2020 | 10 | 0.050 |
Why?
| Wharton Jelly | 1 | 2020 | 1 | 0.050 |
Why?
| Uganda | 1 | 2020 | 36 | 0.050 |
Why?
| Herpesvirus 4, Human | 1 | 2020 | 35 | 0.050 |
Why?
| Body Composition | 1 | 2003 | 318 | 0.050 |
Why?
| Cell Shape | 1 | 2020 | 20 | 0.050 |
Why?
| Software | 1 | 2003 | 273 | 0.050 |
Why?
| Neisseria gonorrhoeae | 1 | 2020 | 4 | 0.050 |
Why?
| Herpesviridae Infections | 1 | 2020 | 46 | 0.040 |
Why?
| Ceftriaxone | 1 | 2020 | 26 | 0.040 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2020 | 53 | 0.040 |
Why?
| B-Lymphocytes | 1 | 2021 | 170 | 0.040 |
Why?
| Drug Resistance, Bacterial | 1 | 2020 | 71 | 0.040 |
Why?
| Thrombocytopenia | 1 | 2020 | 85 | 0.040 |
Why?
| Cohort Studies | 2 | 2018 | 1422 | 0.040 |
Why?
| Remission Induction | 2 | 2012 | 207 | 0.040 |
Why?
| Proctoscopy | 1 | 2019 | 2 | 0.040 |
Why?
| Interleukin-6 | 2 | 2016 | 264 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 466 | 0.040 |
Why?
| Microbial Sensitivity Tests | 1 | 2020 | 269 | 0.040 |
Why?
| Cell Survival | 1 | 2020 | 600 | 0.040 |
Why?
| Masks | 1 | 2018 | 30 | 0.040 |
Why?
| Statistics, Nonparametric | 2 | 2013 | 194 | 0.040 |
Why?
| Receptors, Chemokine | 1 | 2017 | 12 | 0.040 |
Why?
| Models, Animal | 1 | 2019 | 233 | 0.040 |
Why?
| Coinfection | 1 | 2018 | 38 | 0.040 |
Why?
| Neurodegenerative Diseases | 1 | 2019 | 76 | 0.040 |
Why?
| Pandemics | 1 | 2022 | 559 | 0.040 |
Why?
| Bone Marrow | 1 | 2019 | 362 | 0.040 |
Why?
| Neurogenesis | 1 | 2017 | 27 | 0.040 |
Why?
| Cell Separation | 1 | 2017 | 89 | 0.040 |
Why?
| Cytological Techniques | 1 | 2017 | 14 | 0.040 |
Why?
| Angiopoietin-2 | 1 | 2017 | 15 | 0.040 |
Why?
| Interleukin-2 | 1 | 2017 | 72 | 0.040 |
Why?
| Angiopoietin-1 | 1 | 2017 | 16 | 0.040 |
Why?
| Receptor, TIE-2 | 1 | 2017 | 16 | 0.040 |
Why?
| Axilla | 1 | 2017 | 89 | 0.040 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2017 | 43 | 0.040 |
Why?
| Fluorouracil | 1 | 2016 | 54 | 0.040 |
Why?
| Staining and Labeling | 1 | 2017 | 97 | 0.040 |
Why?
| Gene Rearrangement | 1 | 2017 | 74 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2017 | 183 | 0.030 |
Why?
| Odds Ratio | 1 | 2018 | 545 | 0.030 |
Why?
| Neuroprotective Agents | 1 | 2017 | 105 | 0.030 |
Why?
| Chemoradiotherapy | 1 | 2016 | 40 | 0.030 |
Why?
| Membrane Glycoproteins | 1 | 2017 | 240 | 0.030 |
Why?
| Interferon-gamma | 1 | 2017 | 177 | 0.030 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2016 | 5 | 0.030 |
Why?
| Mastectomy | 1 | 2017 | 140 | 0.030 |
Why?
| Directly Observed Therapy | 1 | 2015 | 8 | 0.030 |
Why?
| Urine | 1 | 2015 | 23 | 0.030 |
Why?
| Reagent Kits, Diagnostic | 1 | 2015 | 18 | 0.030 |
Why?
| Vaginal Smears | 1 | 2015 | 28 | 0.030 |
Why?
| Neoadjuvant Therapy | 1 | 2017 | 114 | 0.030 |
Why?
| RNA, Viral | 2 | 2009 | 125 | 0.030 |
Why?
| Neovascularization, Pathologic | 1 | 2017 | 161 | 0.030 |
Why?
| Treatment Failure | 1 | 2015 | 114 | 0.030 |
Why?
| Prisons | 1 | 2015 | 38 | 0.030 |
Why?
| Ifosfamide | 1 | 2015 | 9 | 0.030 |
Why?
| Cytarabine | 1 | 2015 | 39 | 0.030 |
Why?
| Flow Cytometry | 1 | 2017 | 476 | 0.030 |
Why?
| Induction Chemotherapy | 1 | 2014 | 60 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 2 | 2006 | 57 | 0.030 |
Why?
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 20 | 0.030 |
Why?
| Depression | 1 | 2019 | 568 | 0.030 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 36 | 0.030 |
Why?
| Melphalan | 1 | 2014 | 174 | 0.030 |
Why?
| Statistics as Topic | 1 | 2013 | 88 | 0.030 |
Why?
| Cancer Care Facilities | 1 | 2013 | 20 | 0.030 |
Why?
| Time | 1 | 2013 | 25 | 0.030 |
Why?
| Administration, Cutaneous | 1 | 2013 | 51 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2013 | 206 | 0.030 |
Why?
| Specialization | 1 | 2013 | 46 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2013 | 119 | 0.030 |
Why?
| Gene Expression Regulation | 1 | 2017 | 976 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 55 | 0.030 |
Why?
| Demography | 1 | 2013 | 93 | 0.030 |
Why?
| Antitrichomonal Agents | 1 | 2012 | 1 | 0.030 |
Why?
| Risk Assessment | 1 | 2017 | 1259 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2014 | 637 | 0.030 |
Why?
| Reference Values | 1 | 2013 | 310 | 0.030 |
Why?
| Polyethylene Glycols | 1 | 2012 | 93 | 0.030 |
Why?
| Medical Oncology | 1 | 2013 | 94 | 0.030 |
Why?
| Antigens, Viral | 1 | 2012 | 44 | 0.030 |
Why?
| Administration, Topical | 1 | 2011 | 56 | 0.020 |
Why?
| Single-Blind Method | 1 | 2011 | 116 | 0.020 |
Why?
| Sex Factors | 1 | 2013 | 691 | 0.020 |
Why?
| Organ Size | 1 | 2011 | 226 | 0.020 |
Why?
| Neoplasm Proteins | 1 | 2013 | 322 | 0.020 |
Why?
| Antibodies, Viral | 1 | 2010 | 88 | 0.020 |
Why?
| Retrospective Studies | 1 | 2022 | 6108 | 0.020 |
Why?
| Survival Rate | 1 | 2012 | 894 | 0.020 |
Why?
| Anti-Retroviral Agents | 1 | 2008 | 14 | 0.020 |
Why?
| Psychiatric Status Rating Scales | 1 | 2009 | 319 | 0.020 |
Why?
| Psychometrics | 1 | 2009 | 224 | 0.020 |
Why?
| Lectins | 1 | 2007 | 14 | 0.020 |
Why?
| Busulfan | 1 | 2008 | 18 | 0.020 |
Why?
| Mutation | 1 | 2013 | 1294 | 0.020 |
Why?
| Glycosylation | 1 | 2007 | 100 | 0.020 |
Why?
| Mice | 1 | 2017 | 5739 | 0.020 |
Why?
| Ultrasonography | 1 | 2008 | 436 | 0.020 |
Why?
| Maximum Tolerated Dose | 1 | 2006 | 37 | 0.020 |
Why?
| Injections, Subcutaneous | 1 | 2006 | 54 | 0.020 |
Why?
| Hypertension, Renal | 1 | 2005 | 22 | 0.020 |
Why?
| Cell Proliferation | 1 | 2009 | 1007 | 0.020 |
Why?
| Fatigue | 1 | 2006 | 117 | 0.020 |
Why?
| Pyridoxine | 1 | 2004 | 4 | 0.020 |
Why?
| Ribonucleotides | 1 | 2004 | 5 | 0.020 |
Why?
| Vitamin B 12 | 1 | 2004 | 27 | 0.020 |
Why?
| Erythrocytes | 1 | 2004 | 83 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2006 | 486 | 0.010 |
Why?
| Adenosine | 1 | 2004 | 69 | 0.010 |
Why?
| Homocysteine | 1 | 2004 | 128 | 0.010 |
Why?
| Receptors, Interleukin-6 | 1 | 2002 | 22 | 0.010 |
Why?
| Endothelial Growth Factors | 1 | 2002 | 9 | 0.010 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2002 | 15 | 0.010 |
Why?
| Lymphokines | 1 | 2002 | 20 | 0.010 |
Why?
| Drug Tolerance | 1 | 2002 | 60 | 0.010 |
Why?
| Safety | 1 | 2002 | 78 | 0.010 |
Why?
| Child, Preschool | 1 | 2005 | 3871 | 0.010 |
Why?
|
|
Lee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|